Jim Shrine

Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug

July 3, 2007

Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug

July 3, 2007

By Jim Shrine

Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

Peregrine Brings In $22.5M To Support Cancer, HCV Studies

July 2, 2007

By Jim Shrine

Peregrine Brings In $22.5M To Support Cancer, HCV Studies

July 2, 2007

By Jim Shrine

Serenex Raises $31M To Fund Mucositis And Hsp90 Programs

June 29, 2007

By Jim Shrine

Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today)

Serenex Raises $31M To Fund Mucositis And Hsp90 Programs

June 29, 2007

By Jim Shrine

Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today)